Baillie Gifford & Co. Has $52.32 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Baillie Gifford & Co. raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 238.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 706,796 shares of the medical research company's stock after buying an additional 498,100 shares during the period. Baillie Gifford & Co. owned about 0.12% of Edwards Lifesciences worth $52,324,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of EW. Harbor Capital Advisors Inc. raised its holdings in shares of Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its holdings in shares of Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock valued at $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $3,702,000. Finally, Avanza Fonder AB bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $4,845,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity

In other news, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company's stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 over the last quarter. 1.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Daiwa America downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 30th. Piper Sandler lifted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Finally, Robert W. Baird dropped their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $79.95.

Edwards Lifesciences Trading Down 2.0 %

NYSE:EW traded down $1.46 during trading hours on Friday, hitting $73.25. The stock had a trading volume of 2,843,619 shares, compared to its average volume of 4,417,774. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $43.20 billion, a price-to-earnings ratio of 10.51, a P/E/G ratio of 4.82 and a beta of 1.10. The business's 50 day moving average is $72.85 and its 200-day moving average is $69.94.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.